A Phase II, Open-Label Study of Bortezomib (Velcade ®), Cladribine, and Rituximab (VCR) in Advanced, Newly Diagnosed and Relapsed/Refractory Mantle Cell and Indolent Lymphomas

Conclusion In summary, we report that VCR is effective in MCL and iNHL. Although hematological toxicity can be an issue, this study demonstrates a high response rate to a novel combination, and provides an alternative option in transplant ineligible R/R MCL and iNHL. Teaser Bortezomib, Cladribine and Rituximab (VCR) is a novel and effective combination in mantle cell and indolent non-Hodgkin’s lymphomas.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research